Ixazomib

BNF:
Immune system & malignant disease
Status:
Red
Decision Date:
March 2018
 

Comments

RED:

  • NICE TA870 - Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (Decision date - March 2023)

NHS England drug. Available through CDF

Red Drug Classifications

  • 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
  • 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
  • 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)

search again

Derby and Derbyshire ICB

Derby and Derbyshire ICB

Please click the button to navigate to our app

Redirect to app